Direct Oral Anticoagulants in Patients with Venous Thromboembolism and Thrombophilia: A systematic review and Meta-analysis: Comment.
J Thromb Haemost. 2019 Mar 08;:
Authors: Dufrost V, Wahl D, Zuily S
In a recent article (1), Elsebaie MA et al. performed a systematic review on direct oral anticoagulants (DOACs) use in venous thromboembolism (VTE) and thrombophilia. In the subgroup of antiphospholipid syndrome (APS) patients and after exclusion of recurrent arterial events, the meta-analysis of six studies (Re-COVER, RE-COVER II, RE-MEDY, EINSTEIN-DVT, EINSTEIN-PE, HOKUSAI VTE, RAPS, TRAPS) suggested that no statistically significant differences were observed between DOACs and warfarin for prevention of recurrent VTE. The authors concluded that this subgroup analysis restricted to APS patients indicated that DOACs could be effective and safe compared to vitamin K antagonists (VKAs). This article is protected by copyright. All rights reserved.
PMID: 30849203 [PubMed - as supplied by publisher]